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Abstract
Background: The use of nanotechnology has led to rapid 
growth in various areas. Thus, health and safety issues of 
nanoparticles (NPs) should be promptly addressed. Manganese 
oxide (MnO
2
) nanoparticles (NPs) are typically used for 
biomedical and industrial applications. However, characterizing 
the potential human health effects of MnO
2
 NPs is required 
before fully exploiting these materials. The aim of this study 
was to investigate the toxicity of MnO
2 
micro- and nanoparticles 
on blood glucose level and lipid profile in male Wistar rats.
Methods: A total of 105 rats were divided into one control and 
two experimental groups. Each experimental group received a 
single subcutaneous injection of MnO
2 
micro- and nanoparticles 
(100 μg/kg), respectively, every two weeks for 14 weeks. Their 
blood glucose, cholesterol, triglycerides, LDL, and HDL levels 
were then measured. The data presented as mean±SEM and 
compared with the repeated measures using the Prism statistical 
software (version 6.0).
Results: Biochemical assessment in plasma samples showed that 
MnO
2 
micro- and nanoparticles injection significantly (P<0.01) 
increased the plasma glucose and cholesterol levels in all and 
few weeks, respectively. MnO
2 
nanoparticles significantly 
(P<0.01) decreased the HDL level in weeks 6, 12, and 14, but 
MnO
2 
microparticles decreased the HDL level only in week 12. 
In both MnO
2 
micro- and nanoparticles groups, LDL alterations 
were near to the control group, except for week 10. However, 
the same treatment had no effect on triglycerides concentrations 
compared to the control group.
Conclusion: Our results show that exposure to nanosized 
particles at subchronic doses caused adverse changes in animal 
biochemical profiles, especially in glucose level. It seems that 
the high oxidative power of these particles is the main reason 
for these disturbances.
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Introduction
The proposed scientific, medical, and technical applications 
of nanomaterials have been greatly increased recently. 
Nanomaterials have unique physicochemical qualities compared 
What’s Known
• Due to their particular 
characteristics and different shapes, 
MnO2 nanoparticles are widely used 
in many fi elds such as electrical 
equipment, cosmetics, catalyzers, 
ceramics, and pigments.
• Toxicological studies have shown 
that these magnetic nanoparticles can 
have adverse effects on the health of 
human beings and other living species.
• Biological safety of  MnO2 
nanoparticles is a controversial issue.
What’s New
• Exposure to nanosized particles 
at subchronic doses caused adverse 
changes in the animals’ biochemical 
profi les, especially at glucose level.
• It seems that the high oxidative 
power of these particles is the main 
reason for these disturbances.
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to micromaterials in terms of size, surface 
structure, solubility, and aggregation. Thus, 
the reduction in particle size from micro- to 
nanoscale might be beneficial for many 
industrial and scientific applications. However, 
nanomaterials have potential toxicities not found 
in micromaterials, which makes it essential to 
understand the biological activity and potential 
toxicity of the former.1,2
High dosage of manganese (Mn) can be 
toxic, but it is crucial for maintaining the proper 
function and regulation of many biological 
processes. Mn is a constituent of many enzymes 
involved in fat and protein metabolism and 
is utilized by various antioxidant enzymes 
such as Mn superoxide dismutase (MnSOD) 
and glutamine synthetase.3,4 Additionally, this 
important element is involved in immune function, 
regulation of blood sugar, production of cellular 
energy, reproduction, digestion, bone growth, 
carbohydrate metabolism, and blood clotting.5
There are many manganese applications in 
different fields such as steel and non-steel alloy 
production companies, battery manufacture, 
colorant, pigments, ferrites, welding fluxes, 
fuel additives (methylcyclopentadienyl 
manganese tricarbonyl), catalysts, and metal 
coating. Manganese oxides have also been 
significant in the environmental remediation, 
MRI diagnosis, and drug and pharmaceutical 
industries.6-8 Manganese oxide (MnO2)-NPs are 
promising materials that are used as contrast 
agents for magnetic resonance imaging (MRI), 
drug delivery, and ionization-assisting reagent 
in mass spectroscopy.9 Mn is also present 
in nanotechnological applications such as 
semiconductor nanocrystals, ZnS, and Mn2+ 
nanoflowers (three-dimensional synthetic 
nanostructures, growing in a flower- or a tree-
like shape).
An increase in the production and use 
of manganese oxide NPs may enhance the 
probable risk of occupationally exposed humans 
and the environment. Occupational exposure 
to Mn can result in neurological disorder, called 
manganism, and is similar to Parkinson disease.10 
Some patients were reported to receive long-
term Mn-supplemented parenteral nutrition, 
hypermanganesaemia and altered magnetic 
resonance imaging (MRI) scans (similar to 
those observed in the case of manganism). In 
fact, one report suggested that even short-term 
total PN therapy with Mn-supplementation might 
cause Mn toxicity in patients with obstructive 
jaundice, followed by an increase in the blood Mn 
concentration as a result of reduced biliary flow.11
Since MnO2 is used as a substrate for 
synthesis of other Mn-containing compounds, 
therefore, a higher rate of contamination of MnO2 
in the environment is reported.
In comparison with other forms of Mn 
particles, MnO2 nanoparticles have a higher 
oxidation power.12 Over the past decade, various 
groups have reported toxicological studies on 
MnO2 nanoparticles, both in vitro and in vivo. 
These results have mainly focused on their 
neurotoxicity, pulmonary toxicity, hepatotoxicity, 
cytotoxic effects, inflammatory response, and 
genotoxicity.13-15 Based on a previous report, 
change in MnO2 particle size affects Mn 
distribution and clearance from CNS.16 Chronic 
administration of MnO2 nano- and microparticles 
were also associated with manganese 
accumulation in hepatic tissue and liver injury.17
In the present study, a 14-week repeated 
subcutaneous dose toxicity of MnO2 nano- and 
microparticles was conducted on plasma 
glucose level and lipid profile in Wistar rats.
Materials and Methods
Animals
In this experimental study, 105 male albino 
Wistar rats (Pasteur Institute, Tehran, Iran) 
weighing 140±10 g were housed in an air-
conditioned colony room on a12-hour light/
dark cycle (21-23°C, humidity of 30-40%) and 
supplied with standard diet and tap water ad 
libitum. Procedures involving animals and their 
care were conducted in conformity with the NIH 
guidelines for the care and use of laboratory 
animals.
The Drug
MnO2 microparticles (figure 1) used in 
this research were purchased from MERCK 
Company, Germany. MnO2 nanoparticles 
were prepared via the hydrothermal 
procedure proposed by Zhang et al., with 
some modification.18 In practice, 20 ml of 
KMnO4 (0.2 mM/lit) were mixed with 16 ml 
MnO4 (0.125 mM/lit) for 5 minutes. The resulting 
mixture was taken directly into a steel autoclave 
with Teflon cover and kept for 16 h at 160°C 
and then was cooled at room temperature. The 
resulting brown product was collected, washed 
with distilled water and ethanol 3 times, and 
dried with the hot air current 80°C for 12 h. 
The resulting particles were scrutinized by an 
electron microscope to ensure that they were 
25 to 85 nanometers in size (figure 2).
The Experimental Groups
Rats were randomly divided into three 
groups,19 namely (i) Control group received 
normal saline (1 ml/kg BW, Sc) for 14 weeks, 
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(ii) MnO2 nanoparticles group received MnO2 
nanoparticles (100 μg/kg in saline, Sc) every two 
weeks for 14 weeks, and (iii) MnO2 microparticles 
group received MnO2 microparticles (100 μg/kg 
in saline, Sc) every two weeks for 14 weeks.
Biochemical Measurements
Five rats were chosen from each group every 
two weeks and were deeply anesthetized with 
ether (Merck). Blood sampling was provided 
directly from the animal heart and the spurting 
blood was collected in clean centrifuge 
tubes and allowed to clot for an hour at room 
temperature. It was then centrifuged at a rate of 
12,000 revolutions per minute (rpm) for 10 min. 
The obtained clear serum was separated and 
labeled for the analysis. The serum levels of 
glucose were measured by glucose oxidase 
method kit (Pars Azmoon, Tehran, Iran) using 
blood chemical analyzer (Vitalab Selectra E, 
UK) and its total cholesterol and triglycerides 
by Enzymatic colorimetric, LDL, HDL were 
measured using standard biochemical kits by 
enzymatic cholesterol assay (Pars Azmoon, 
Tehran, Iran).
Statistical Analysis
The data presented as mean±SEM and 
compared using the repeated measurements. 
P values≤0.05 were considered statistically 
significant. Data analysis was performed using 
Prism statistical software (version 6.0).
Results
Weight Gain Changes
The rats’ body weight gain during the 
14 weeks of treatment (figure 3) showed some 
difference between the groups. The body weight 
gain of animals treated with nanoparticles was 
continuous during the whole treatment, and 
significantly (P<0.05) increased compared to the 
untreated control group during weeks 10 to 14 
after injection. The weight gain of rats receiving 
the same dose of microparticles during weeks 8 
to 14 was significantly (P<0.05) lower than the 
control group.
Biochemical Results
The results of serum glucose level in 
groups 14 weeks after injections are shown 
in figure 4. MnO2 micro- and nanoparticles 
injection significantly (P<0.01) increased the 
blood glucose level in all weeks. However, the 
Figure 1: A scanning electron micrograph of MnO2 
microparticles.
Figure 2: A scanning electron micrograph of MnO2 
nanoparticles.
Figure 3: Comparison of body weight of rats (n=6) in MnO2 
microparticles or nanoparticles (100 μg/kg) treated groups 
during 14 weeks. Repeated measurement test showed 
a significant (P<0.05) difference in body weight between 
groups. *Control vs. Nanoparticle and microparticle groups; 
#Nanoparticle vs. Microparticle groups.
Figure 4: Comparison of blood glucose level of rat (n=6) 
in MnO2 microparticles or nanoparticles (100 μg/kg) 
treated groups during 14 weeks. Repeated measurement 
test showed a significant (P<0.05) difference in blood 
glucose level between groups. *Control vs. Nanoparticle 
and microparticle groups, #: Nanoparticle vs. Microparticle 
groups.
MnO2 micro and nanoparticles toxicity
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same treatment had no effect on triglycerides 
concentrations, compared to the control group 
(figure 5).
Table 1 shows the effect of manganese 
particles toxicity on cholesterol level. The 
cholesterol level in MnO2 nanoparticles group 
was initially decreased and then significantly 
increased in weeks 4, 8 and after week 14 
compared to control. In MnO2 microparticles 
group, cholesterol level had fluctuation compared 
with the control group. At first, it presented a 
decrease and then it significantly increased until 
week 10 and after week 14.
MnO2 nano- and microparticles significantly 
(P<0.01) decreased the HDL level until week 8. 
However, MnO2 nanoparticles increased the HDL 
level at week 14, which was significantly more 
than the control group (table 2).
In MnO2 nanoparticles groups, LDL alterations 
in weeks 2 and 4 were near to the control group, 
and then in most weeks, it was significantly less 
than the control group. The LDL level in MnO2 
microparticles groups significantly (P<0.01) 
decreased, compared to controls (table 3).
Discussion
As the results of the present study indicated, 
body weight gain of the animals treated with 
MnO2 nanoparticles significantly increased 
compared to microparticle groups in which a 
significant decrease was observed.
The present investigation also demonstrated 
that exposure to micro- and nanoparticles of 
MnO2 induced significant hyperglycemia effect 
in rats. It is important to understand the cause 
of changes in body weight gain and glucose 
level and their correlation induced by MnO2 
particles. Hyperglycemia disorder is caused 
by the relative deficiency of insulin secretion 
and varying degrees of insulin resistance and 
is characterized by high circulating glucose. 
Several pathogenic pathways are activated in 
diabetes among which reactive oxygen species 
(ROS), generated by high glucose levels, are 
responsible for metabolic abnormalities and 
chronic complications.20 A counteractive defense 
system is being maintained. Moreover, any 
Figure 5: Comparison of blood triglyceride level of rat (n=6) 
in MnO2 microparticles or nanoparticles (100 μg/kg) treated 
groups during the 14 weeks. Repeated measurement test 
showed a significant (P<0.05) difference in triglyceride 
between groups. *Control vs. Nanoparticle and microparticle 
groups, #: Nanoparticles. Microparticle groups.
Table 1: Comparison of blood cholesterol level of rat (n=6) 
in MnO2 microparticles or nanoparticles (100 μg/kg) 
treated groups during the 14 weeks 
Days Control Nanoparticle Microparticle
0 69±7 71±6 66±8
2 71±7 58±5 54±7
4 68±6 120±9 87±8
6 67±8 62±5 82±8
8 69±5 112±8* (P=0.04) 102±9# (P=0.0019)
10 73±7 72±7 90±9
12 71±8 81±6 63±7
14 70±5 73±6 69±6
*Control vs. Nanoparticle and microparticles groups; 
#Nanoparticles vs. Microparticle groups. Repeated 
measurement test showed a significant (P<0.05) 
difference in LDL level between groups
Table 2: Comparison of blood HDL level of rat (n=6) in 
MnO2 microparticles or nanoparticles (100 μg/kg) treated 
groups during 14 weeks
Days Control Nanoparticle Microparticle
0 41±2 39±2 38±3
2 40±2 20±1* (P=0.002) 14.6±0.7# (P=0.0006), 
& (P=0.0016)
4 38±5 11±1* (P=0.0001) 10.6±0.5# (P=0.0001) 
& (P=0.0001)
6 35±7 14±2* (P=0.0002) 36±2# (P=0.0002)
8 42±4 16.5±1* (P=0.004) 26.4±1
10 40±5 43±3 47±2
12 33±6 49±3* (P=0.002) 23.2±0.5# (P=0.0001) 
14 37±4 54±4* (P=0.0001) 29.8±1# (P=0.002)
*Control vs. Nanoparticle and microparticles groups; 
#Nanoparticles vs. Microparticle groups. Repeated 
measurement test showed a significant (P<0.05) 
difference in HDL between groups
Table 3: Comparison of blood LDL level of rat (n=6) in 
MnO2 microparticles or nanoparticles (100 μg/kg) treated 
groups during the 14 weeks 
Days Control Nanoparticle Microparticle
0 36.4±3 35.7±5 33.5±3
2 34.5±5 35±4 18±5
4 31.7±7 32±7 27±7
6 36.2±3 16.5±6*(P=0.0001) 27±3
8 38±3 45±8 18±8# (P=0.0197)
10 34±5 17±4 19±5
12 33±6 15±4* (P=0.002) 14±3
14 30±5 11±5* (P=0.002) 16±4
*Control vs. Nanoparticle and microparticle groups; 
#Nanoparticle vs. Microparticle groups. Repeated 
measurement test showed a significant (P<0.05) 
difference in LDL level between groups
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imbalance in the production and scavenging 
of ROS leads to excessive levels of either 
molecular oxygen or ROS. Hence, resulting in 
increased ‘oxidative stress’.21
MnO2 nanoparticles have a higher oxidation 
power in comparison with other forms of 
Mn particles.12 Deng Q. et al. proposed that 
manganese is transported to organs rich in 
mitochondria (in particular the liver, pancreas, 
and pituitary) where it is rapidly concentrated.22 
The ability of MnO2 nanoparticles in generating 
ROS and induction of lipid peroxidation, restore 
the imbalances in the antioxidants and liver 
enzymes responsible for the cell dysfunction 
and destruction; and might lead to tissue injury 
and hyperglycemia in our test groups.
Since the K+-ATPase has a significant role in 
insulin secretion of the pancreas; hyperglycemia 
indicates that insulin secretion process may 
be affected by MnO2. It has been reported that 
activities of total, Na+/K+, Mg2+ and Ca2+/ATPases 
are significantly inhibited in a dose-dependent 
manner in rats’ brain after exposure to MnO2-
NPs. Further, higher doses of MnO2-MPs also 
show inhibition of ATPase in rats. Huang et al. 
observed a significant decrease in the activities 
of Na+/K+, Mg2+ and Ca2+/ATPases in hepatocyte 
mitochondria after 30 days of i.p. exposure of 
MnCl2 in male Sprague-Dawley rats.
23 There has 
been no study, until now, which has investigated 
the effects of MnO2 nanoparticles in blood 
glucose.
In the present study, MnO2 nanoparticle 
showed to be quite effective in lipid metabolism 
by the decreased LDL and HDL fraction and 
the increased plasma cholesterol without 
a concomitant increase in triglycerides. In 
comparison to controls, rats exposed to MnO2 
nanoparticles displayed lower HDL-cholesterol 
concentrations in plasma until week 10. The 
evidence for MnO2-induced disruptions in 
lipid metabolism is shown in the increase of 
cholesterol and decrease of HDL and LDL levels 
in plasma without a concomitant increase in 
triglycerides. There is no study about the effect 
of MnO2 nanoparticle on lipid profile.
The various forms of lipids cannot dissolve 
in the blood and must be transported to/and 
from the cells by low-density and high-density 
lipoproteins. High-density lipoprotein cholesterol 
(HDL-C) tends to carry cholesterol away from 
the arteries back to the liver. As a result, high 
serum cholesterol level can be achieved due to 
hepatic dysfunction.24,25 HDL enables lipids like 
cholesterol and triglycerides to be transported 
within the water-based bloodstream. HDL 
particles are able to remove cholesterol from 
within artery atheroma and transport it back 
to the liver for excretion or re-utilization, which 
is the main reason for calling that cholesterol 
carried within HDL particles (HDL-C) “good 
cholesterol” (despite the fact that it is exactly 
the same as that cholesterol in LDL particles). 
Those with higher levels of HDL-C seem to have 
fewer problems with cardiovascular diseases 
while those with low HDL-C cholesterol levels 
increase the rate of heart disease.26 When LDL 
particles are within the blood vessel walls and 
oxidized by free radicals, they appear harmless. 
In previous studies, it has been reported that the 
administration of other metals such as lead and 
cadmium to experimental animals affects lipid 
metabolism.27
The histopathological studies at our laboratory 
have revealed the toxic effects of nanoparticles 
on the liver and kidney organs.28 MnO2 exposure 
produced pronounced hepatic histopathology; 
evidenced by histological alternations in the 
liver, including focal necrosis with hepatocyte 
vacuolization and swelling, pyknotic nuclei, 
and dilation of central vein and sinusoids. It is 
reported that nanoparticles interact with proteins 
and enzymes and interfere with the antioxidant 
defense mechanism, leading to ROS generation 
causing apoptosis and necrosis.29 A previous study 
reported a significant increase in DNA damage 
in leukocytes, micronuclei and chromosomal 
aberrations in bone marrow cells after exposure 
to MnO2-NPs and MnO2-MPs. In addition, DNA 
damage and ROS production were reported in 
the liver organ when MnCl2 was given in drinking 
water to male Wistar rats for 30 consecutive 
days.30 Likewise, MnCl2 injected i.p. in rats at 
5, 10, and 20 mg/kg B.W daily for 3 months, 
showed a significant increase in mitochondrial 
DNA damage in the rat brain and liver.31
The mechanisms responsible for the 
genotoxicity of NPs involve oxidative stress, 
which causes redox imbalance within cells 
usually as a result of an increase in intracellular 
ROS.30 Similarly, oral administration of 
MnCl2 (20 mg/ml) for 30 days increased the 
activities of hepatotoxicity biomarkers such 
as AST, ALT, and LDH levels compared to the 
control in male Wistar rats.31
Recently, many studies have been conducted 
on the application of (MnO2)-NPS in MRI and 
drug delivery. However, their toxic effects cannot 
be ignored. In the case of probable toxic effect, 
it could depend on various factors such as 
exposure duration.
Conclusion
The toxicity of repeated subcutaneous injection 
of manganese nanoparticles (25-85 nm) in a 
MnO2 micro and nanoparticles toxicity
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rat was studied comparatively with manganese 
microparticles (3m). Both particles induced 
hyperglycemia and alteration of serum lipid profile 
in male Wistar rats. Therefore, it can be concluded 
that both particles adversely affect the serum lipid 
profile and glucose level. This study is the first to 
report on the toxicity of MnO2 nanoparticles.
This study was designed to achieve its 
objectives as mentioned above. However, the 
potential limitation of the study was changes in 
manganese in serum and the synthesis MnO2 
nanoparticles. This can be addressed in future 
studies to elucidate the role of oxidative stress by 
measurement (GSH and antioxidant enzymes, 
e.g. SOD). The results of the present study 
suggest that MnO2 nano- and microparticles 
induced pancreas toxicity, providing further 
details of the molecular mechanism underlying 
MnO2 toxicity.
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